Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2409-2419

  Wang, Jiun Ling ^a,b   Chang, Chia Hsuin ^b,c   Young Xu, Yinong ^d   Chan, K Arnold ^e  

^a I SHOU UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d EpiPatterns   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; MICAFUNGIN; VORICONAZOLE;

ARTICLE; CANDIDIASIS; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MAXIMUM LIKELIHOOD METHOD; META ANALYSIS; MYCOSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER; MYCOSES; RISK FACTORS;

EID: 77952651855     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01657-09     Document Type: Article

References (90)

1. Abele-Horn, M., A. Kopp, U. Sternberg, A. Ohly, A. Dauber, W. Russwurm, W. Buchinger, O. Nagengast, and P. Emmerling. 1996. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 24:426-432. (Pubitemid 27023090)
2. Agresti, A., and B. Coull. 1998. Approximate is better than 'exact' for interval estimation of binomial proportions. Am. Stat. 52:119-126.
3. Anaissie, E. J., R. O. Darouiche, D. Abi-Said, O. Uzun, J. Mera, L. O. Gentry, T. Williams, D. P. Kontoyiannis, C. L. Karl, and G. P. Bodey. 1996. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23:964-972.
4. Bates, D. W., L. Su, D. T. Yu, G. M. Chertow, D. L. Seger, D. R. Gomes, E. J. Dasbach, and R. Platt. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32:686-693.
5. Betts, R. F., M. Nucci, D. Talwar, M. Gareca, F. Queiroz-Telles, R. J. Bedimo, R. Herbrecht, G. Ruiz-Palacios, J. A. Young, J. W. Baddley, K. M. Strohmaier, K. A. Tucker, A. F. Taylor, and N. A. Kartsonis. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48:1676-1684.
6. Boogaerts, M., D. J. Winston, E. J. Bow, G. Garber, A. C. Reboli, A. P. Schwarer, N. Novitzky, A. Boehme, E. Chwetzoff, and K. De Beule. 2001. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med. 135:412-422.
7. Bow, E. J. 2008. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br. J. Haematol. 140:133-152.
8. Bowden, R., P. Chandrasekar, M. H. White, X. Li, L. Pietrelli, M. Gurwith, J. A. van Burik, M. Laverdiere, S. Safrin, and J. R. Wingard. 2002. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35:359-366.
9. Bradbury, B. D., and S. S. Jick. 2002. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 22:697-700.
10. Chamilos, G., M. Luna, R. E. Lewis, R. Chemaly, I. I. Raad, and D. P. Kontoyiannis. 2007. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin. Ther. 29:1980-1986.
11. Chang, C. H., Y. Young-Xu, T. Kurth, J. E. Orav, and A. K. Chan. 2007. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am. J. Med. 120:791-798.
12. Chuang-Stein, C. 1993. An application of the beta-binomial model to combine and monitor medical event rates in clinical trials. Drug Infect. J. 27: 515-523. (Pubitemid 23167370)
13. Cornely, O. A., J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H. A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, and R. Herbrecht. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a highloading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
14. Daniel, W. 1997. Probability distribution. In Biostatistics: a foundation for analysis in the health sciences, 7th ed. John Wiley & Sons, Inc., New York, NY.
15. den Hollander, J. G., C. van Arkel, B. J. Rijnders, P. J. Lugtenburg, S. de Marie, and M. D. Levin. 2006. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J. Antimicrob. Chemother. 57:1248-1250.
16. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
17. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
18. Dismukes, W. E. 2006. Antifungal therapy: lessons learned over the past 27 years. Clin. Infect. Dis. 42:1289-1296.
19. Eggimann, P., J. Garbino, and D. Pittet. 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3:685-702.
20. Ellis, M., A. Shamoon, W. Gorka, F. Zwaan, and B. al-Ramadi. 2001. Severe hepatic injury associated with lipid formulations of amphotericin B. Clin. Infect. Dis. 32:E87-E89.
21. Ellis, M., D. Spence, B. de Pauw, F. Meunier, A. Marinus, L. Collette, R. Sylvester, J. Meis, M. Boogaerts, D. Selleslag, V. Krcmery, W. von Sinner, P. MacDonald, C. Doyen, and B. Vandercam. 1998. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 27:1406-1412.
22. Ellis, M. E., M. A. Halim, D. Spence, P. Ernst, H. Clink, M. Kalin, F. Baillie, and W. Greer. 1995. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever-preliminary observations from a pilot, exploratory study. J. Infect. 30:141-146.
23. EORTC International Antimicrobial Therapy Cooperative Group. 1989. Empiric antifungal therapy in febrile granulocytopenic patients. Am. J. Med. 86:668-672.
24. Falagas, M. E., F. Ntziora, G. I. Betsi, and G. Samonis. 2007. Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. Int. J. Antimicrob. Agents 29:136-143.
25. Fischer, M. A., W. C. Winkelmayer, R. H. Rubin, and J. Avorn. 2005. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin. Infect. Dis. 41:301-307.
26. Fleming, R. V., H. M. Kantarjian, R. Husni, K. Rolston, J. Lim, I. Raad, S. Pierce, J. Cortes, and E. Estey. 2001. Comparison of amphotericin B lipid complex (ABLC) vs. Ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma 40: 511-520.
27. Gafter-Gvili, A., L. Vidal, E. Goldberg, L. Leibovici, and M. Paul. 2008. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin. Proc. 83:1011-1021.
28. Girois, S. B., F. Chapuis, E. Decullier, and B. G. Revol. 2006. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 25:138-149.
29. Goldberg, E., A. Gafter-Gvili, E. Robenshtok, L. Leibovici, and M. Paul. 2008. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur. J. Cancer 44:2192-2203.
30. Guimarães, P. 2005. A simple approach to fit the beta-binomial model. Stata J. 5:385-394. (Pubitemid 43708470)
31. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
32. Hughes, W. T., D. Armstrong, G. P. Bodey, E. J. Bow, A. E. Brown, T. Calandra, R. Feld, P. A. Pizzo, K. V. Rolston, J. L. Shenep, and L. S. Young. 2002. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:730-751.
33. Imhof, A., R. B. Walter, and A. Schaffner. 2003. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. 36:943-951.
34. Jorgensen, K. J., P. C. Gotzsche, and H. K. Johansen. 2006. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Systematic Review CD004707.
35. Kim, H., and C. Bindslev-Jensen. 2004. Reported case of severe hepatotoxicity likely due to fluconazole and not desloratadine. Acta Haematol. 112: 177-178. (Pubitemid 39274168)
36. Krause, D. S., J. Reinhardt, J. A. Vazquez, A. Reboli, B. P. Goldstein, M. Wible, and T. Henkel. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48:2021-2024.
37. Kujath, P., K. Lerch, P. Kochendorfer, and C. Boos. 1993. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 21:376-382.
38. Kullberg, B. J., J. D. Sobel, M. Ruhnke, P. G. Pappas, C. Viscoli, J. H. Rex, J. D. Cleary, E. Rubinstein, L. W. Church, J. M. Brown, H. T. Schlamm, I. T. Oborska, F. Hilton, and M. R. Hodges. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442.
39. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
40. Langman, L. J., and F. Boakye-Agyeman. 2007. Measurement of voriconazole in serum and plasma. Clin. Biochem. 40:1378-1385.
41. Leather, H. L., and J. R. Wingard. 2002. Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom? Curr. Opin. Infect. Dis. 15:369-375.
42. Leenders, A. C., S. Daenen, R. L. Jansen, W. C. Hop, B. Lowenberg, P. W. Wijermans, J. Cornelissen, R. Herbrecht, H. van der Lelie, H. C. Hoogsteden, H. A. Verbrugh, and S. de Marie. 1998. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol. 103:205-212.
43. Levin, M. D., J. G. den Hollander, B. van der Holt, B. J. Rijnders, M. van Vliet, P. Sonneveld, and R. H. van Schaik. 2007. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J. Antimicrob. Chemother. 60:1104-1107.
44. Lewis, R. E. 2008. What is the "therapeutic range" for voriconazole? Clin. Infect. Dis. 46:212-214.
45. Lutsar, I., M. R. Hodges, K. Tomaszewski, P. F. Troke, and N. D. Wood. 2003. Safety of voriconazole and dose individualization. Clin. Infect. Dis. 36:1087-1088.
46. Malik, I. A., I. Moid, Z. Aziz, S. Khan, and M. Suleman. 1998. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am. J. Med. 105: 478-483.
47. McCormack, P. L., and C. M. Perry. 2005. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 65:2049-2068. (Pubitemid 41327370)
48. Mikus, G., V. Schowel, M. Drzewinska, J. Rengelshausen, R. Ding, K. D. Riedel, J. Burhenne, J. Weiss, T. Thomsen, and W. E. Haefeli. 2006. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther. 80:126-135.
49. Miller, M. A. 1984. Reversible hepatotoxicity related to amphotericin B. Can. Med. Assoc. J. 131:1245-1247.
50. Mills, E. J., D. Perri, C. Cooper, J. B. Nachega, P. Wu, I. Tleyjeh, and P. Phillips. 2009. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann. Clin. Microbiol. Antimicrob. 8:23.
51. Moher, D., D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D. F. Stroup. 1999. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-Analyses. Lancet 354:1896-1900.
52. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
53. Nivoix, Y., M. Velten, V. Letscher-Bru, A. Moghaddam, S. Natarajan-Ame, C. Fohrer, B. Lioure, K. Bilger, P. Lutun, L. Marcellin, A. Launoy, G. Freys, J. P. Bergerat, and R. Herbrecht. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47:1176-1184.
54. Nucci, M., M. Loureiro, F. Silveira, A. R. Casali, L. F. Bouzas, E. Velasco, N. Spector, and W. Pulcheri. 1999. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob. Agents Chemother. 43:1445-1448.
55. Pachl, J., P. Svoboda, F. Jacobs, K. Vandewoude, B. van der Hoven, P. Spronk, G. Masterson, M. Malbrain, M. Aoun, J. Garbino, J. Takala, L. Drgona, J. Burnie, and R. Matthews. 2006. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42:1404-1413.
56. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
57. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
58. Pascual, A., T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
59. Patterson, T. F. 2005. Advances and challenges in management of invasive mycoses. Lancet 366:1013-1025. (Pubitemid 41323037)
60. Patterson, T. F., H. W. Boucher, R. Herbrecht, D. W. Denning, O. Lortholary, P. Ribaud, R. H. Rubin, J. R. Wingard, B. DePauw, H. T. Schlamm, P. Troke, and J. E. Bennett. 2005. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin. Infect. Dis. 41:1448-1452.
61. Potoski, B. A., and J. Brown. 2002. The safety of voriconazole. Clin. Infect. Dis. 35:1273-1275.
62. Prentice, H. G., I. M. Hann, R. Herbrecht, M. Aoun, S. Kvaloy, D. Catovsky, C. R. Pinkerton, S. A. Schey, F. Jacobs, A. Oakhill, R. F. Stevens, P. J. Darbyshire, and B. E. Gibson. 1997. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98:711-718.
63. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
64. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331:1325-1330.
65. Rex, J. H., P. G. Pappas, A. W. Karchmer, J. Sobel, J. E. Edwards, S. Hadley, C. Brass, J. A. Vazquez, S. W. Chapman, H. W. Horowitz, M. Zervos, D. McKinsey, J. Lee, T. Babinchak, R. W. Bradsher, J. D. Cleary, D. M. Cohen, L. Danziger, M. Goldman, J. Goodman, E. Hilton, N. E. Hyslop, D. H. Kett, J. Lutz, R. H. Rubin, W. M. Scheld, M. Schuster, B. Simmons, D. K. Stein, R. G. Washburn, L. Mautner, T. C. Chu, H. Panzer, R. B. Rosenstein, and J. Booth. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
66. Riedel, A., L. Choe, J. Inciardi, C. Yuen, T. Martin, and B. J. Guglielmo. 2007. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect. Dis. 7:70.
67. Robenshtok, E., A. Gafter-Gvili, E. Goldberg, M. Weinberger, M. Yeshurun, L. Leibovici, and M. Paul. 2007. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J. Clin. Oncol. 25:5471-5489.
68. Sable, C. A., K. M. Strohmaier, and J. A. Chodakewitz. 2008. Advances in antifungal therapy. Annu. Rev. Med. 59:361-379.
69. Schoffski, P., M. Freund, R. Wunder, D. Petersen, C. H. Kohne, H. Hecker, U. Schubert, and A. Ganser. 1998. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 317:379-384. (Pubitemid 28359309)
70. Schuler, U., S. Bammer, W. E. Aulitzky, C. Binder, A. Bohme, G. Egerer, M. Sandherr, R. Schwerdtfeger, G. Silling, H. Wandt, A. Glasmacher, and G. Ehninger. 2007. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 30:185-191.
71. Scott, L. J., and D. Simpson. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298.
72. Silling, G., W. Fegeler, N. Roos, M. Essink, and T. Buchner. 1999. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 42(Suppl. 2):101-104. (Pubitemid 30253120)
73. Sobel, J. D., and S. G. Revankar. 2007. Echinocandins-first-choice or firstline therapy for invasive candidiasis? N. Engl. J. Med. 356:2525-2526.
74. Song, J. C., and S. Deresinski. 2005. Hepatotoxicity of antifungal agents. Curr. Opin. Invest. Drugs 6:170-177.
75. Subira, M., R. Martino, L. Gomez, J. M. Marti, C. Estany, and J. Sierra. 2004. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur. J. Haematol. 72:342-347.
76. Tarone, R. E. 1979. Testing the goodness of fit of the binomial distribution. Biometrika 66:585-590.
77. van't Wout, J. W., I. Novakova, C. A. Verhagen, W. E. Fibbe, B. E. de Pauw, and J. W. van der Meer. 1991. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J. Infect. 22:45-52.
78. Reference deleted.
79. Verweij, P. E., J. P. Donnelly, B. J. Kullberg, J. F. Meis, and B. E. De Pauw. 1994. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 22:81-85.
80. Viscoli, C., E. Castagnola, M. T. Van Lint, C. Moroni, A. Garaventa, M. R. Rossi, R. Fanci, F. Menichetti, D. Caselli, M. Giacchino, and M. Congiu. 1996. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur. J. Cancer 32A:814-820.
81. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
82. Walsh, T. J., R. W. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, D. Bodensteiner, P. Pappas, N. Seibel, R. N. Greenberg, S. Dummer, M. Schuster, and J. S. Holcenberg. 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340:764-771.
83. Walsh, T. J., J. W. Hiemenz, N. L. Seibel, J. R. Perfect, G. Horwith, L. Lee, J. L. Silber, M. J. DiNubile, A. Reboli, E. Bow, J. Lister, and E. J. Anaissie. 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26:1383-1396.
84. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinhardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, E. Anaissie, and J. Lee. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.
85. Walsh, T. J., M. Rubin, J. Hathorn, J. Gress, M. Thaler, J. Skelton, J. McKnight, M. Browne, D. Marshall, D. Cotton, et al. 1991. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch. Intern. Med. 151:765-770.
86. Walsh, T. J., H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Cornely, M. R. Bourque, R. J. Lupinacci, C. A. Sable, and B. E. dePauw. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.
87. White, M. H., R. A. Bowden, E. S. Sandler, M. L. Graham, G. A. Noskin, J. R. Wingard, M. Goldman, J. A. van Burik, A. McCabe, J. S. Lin, M. Gurwith, and C. B. Miller. 1998. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 27:296-302.
88. Wingard, J. R., and H. Leather. 2005. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin. Infect. Dis. 41:308-310.
89. Wingard, J. R., M. H. White, E. Anaissie, J. Raffalli, J. Goodman, and A. Arrieta. 2000. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31:1155-1163.
90. Winston, D. J., J. W. Hathorn, M. G. Schuster, G. J. Schiller, and M. C. Territo. 2000. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med. 108:282-289.